Document is current
Any future updates will be listed below
-
Authors
Mimouni, Maroua
Bulsei, Julie
Darlington, Meryl
Estellat, Candice
Rouzet, François
Hyafil, Fabien
Durand-Zaleski, Isabelle
,
Chequer, Renata
Ducrocq, Gregory
Alfaiate, Toni
Regaieg, Hamza
Abtan, Jérémie
Leygnac, Sébastien
Milliner, Milan
Burg, Samuel
Azzouna, Rana Ben
Potier, Louis
Laouénan, Cédric
Quintin, Caroline
Roussel, Ronan
Steg, Gabriel
Le Guludec, Dominique
Sorbets, Emmanuel
Imbert, Laetitia
Marie, Pierre-Yves
Hartemann, Agnès
Montalescot, Gilles
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01679886 at ClinicalTrials.govDocuments that mention this clinical trial
Cost-effectiveness of 82-Rubidium PET myocardial perfusion imaging for the diagnosis of myocardial ischemia depending on the prevalence of coronary artery disease
https://doi.org/10.1186/s13550-023-00954-x
-
Funding
Funding for this research was provided by:
French Ministry of Health (AOM11066)
- License Information
-
More Information
Article History
Received: 16 November 2022
Accepted: 15 January 2023
First Online: 8 February 2023
Declarations
:
: The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. All patients provided signed informed consent; the full description of the study design has been registered on clinicaltrials.gov (NCT01679886; ). The French Institutional Review Board approved the study protocol (IRB number: 2012-A00552-41).
: Not applicable.
: Fabien Hyafil is Consultant for Naogen, Curium Pharma, Blue Earth Diagnostics, Novo Nordisk and shareholder of Naogen. The other authors declare no competing interests.
